Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
Go back to Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis| Amgen Inc (NASDAQ: AMGN) | Delayed: 393.17 -44.06 (10.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $437.23 | 52 Week High | $176.85 | |||
| Open | $408.90 | 52 Week Low | $133.64 | |||
| Day High | $410.03 | P/E | 59.21 | |||
| Day Low | $391.17 | EPS | $6.64 | |||
| Volume | 6,663,512 | |||||

